KR20190128660A - 암의 치료에 이용하기 위한 usl-311 - Google Patents

암의 치료에 이용하기 위한 usl-311 Download PDF

Info

Publication number
KR20190128660A
KR20190128660A KR1020197028679A KR20197028679A KR20190128660A KR 20190128660 A KR20190128660 A KR 20190128660A KR 1020197028679 A KR1020197028679 A KR 1020197028679A KR 20197028679 A KR20197028679 A KR 20197028679A KR 20190128660 A KR20190128660 A KR 20190128660A
Authority
KR
South Korea
Prior art keywords
cancer
sdf
fpkm
level
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197028679A
Other languages
English (en)
Korean (ko)
Inventor
피터 리차드슨
Original Assignee
프록시마겐, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프록시마겐, 엘엘씨 filed Critical 프록시마겐, 엘엘씨
Publication of KR20190128660A publication Critical patent/KR20190128660A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197028679A 2017-03-10 2018-03-09 암의 치료에 이용하기 위한 usl-311 Ceased KR20190128660A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
GB1703907.4 2017-03-10
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20190128660A true KR20190128660A (ko) 2019-11-18

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028679A Ceased KR20190128660A (ko) 2017-03-10 2018-03-09 암의 치료에 이용하기 위한 usl-311

Country Status (14)

Country Link
US (1) US20200281937A1 (enExample)
EP (1) EP3592356A1 (enExample)
JP (1) JP2020514345A (enExample)
KR (1) KR20190128660A (enExample)
CN (1) CN110520130A (enExample)
AU (1) AU2018231664A1 (enExample)
BR (1) BR112019018482A2 (enExample)
CA (1) CA3055470A1 (enExample)
EA (1) EA201992130A1 (enExample)
GB (1) GB201703907D0 (enExample)
IL (1) IL269121A (enExample)
MX (1) MX2019010679A (enExample)
SG (1) SG11201908166UA (enExample)
WO (1) WO2018162924A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
PL3277284T3 (pl) 2015-04-02 2021-03-08 Proximagen, Llc Nowe terapie nowotworu

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
PL3277284T3 (pl) * 2015-04-02 2021-03-08 Proximagen, Llc Nowe terapie nowotworu
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Also Published As

Publication number Publication date
SG11201908166UA (en) 2019-10-30
AU2018231664A1 (en) 2019-09-26
EA201992130A1 (ru) 2020-02-04
CA3055470A1 (en) 2018-09-13
BR112019018482A2 (pt) 2020-04-14
EP3592356A1 (en) 2020-01-15
CN110520130A (zh) 2019-11-29
US20200281937A1 (en) 2020-09-10
GB201703907D0 (en) 2017-04-26
JP2020514345A (ja) 2020-05-21
MX2019010679A (es) 2020-02-05
IL269121A (en) 2019-11-28
WO2018162924A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
EP3843850B1 (en) Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases
CN111971279B (zh) 趋化因子受体调节剂及其用途
US11369616B2 (en) Drug combination and its use in therapy
EP3618829B1 (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
US11220492B2 (en) Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
CN114364667A (zh) 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途
TW202134216A (zh) HIF-2α抑制劑
JP2021531314A (ja) ピリドンａ２ｒアンタゴニスト
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
US20230338377A1 (en) Dosing with an azolopyrimidine compound
TW202442653A (zh) Ｋｒａｓ調節化合物
TW202508564A (zh) Ｋｒａｓ調節化合物
KR20190128660A (ko) 암의 치료에 이용하기 위한 usl-311
TWI745824B (zh) 作為tam及met激酶抑制劑之喹啉化合物
CN119585256A (zh) 趋化因子受体调节剂及其用途
KR20240012522A (ko) Egfr 및/또는 her2의 이상을 갖는 암이 있는 대상체의 치료 방법
TW202517264A (zh) Ｋｒａｓ ｇ１２ｄ調節化合物
TW202519517A (zh) Ｐａｒｐ７抑制劑
WO2016098042A1 (en) Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
Jun et al. Discovery of Novel Triple A1/A2A/A2B Adenosine Receptor Antagonists for Cancer Immunotherapy
TW202504894A (zh) Ｐａｒｐ７抑制劑
TW202408519A (zh) Ｃｄ７３化合物
HK40053753A (en) Quinoline compounds as inhibitors of tam and met kinases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230424

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230703

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230424

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I